Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis
Background. Interstitial lung disease (ILD) is the most common complication of systemic sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta-analysis was to provide an estimate of the safety and efficacy profile of Mycophenolate Mofetil (MMF) or sodium (MMS) in SSc-ILD patient...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Pulmonary Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/143637 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552310995156992 |
|---|---|
| author | Argyris Tzouvelekis Nikolaos Galanopoulos Evangelos Bouros George Kolios George Zacharis Paschalis Ntolios Andreas Koulelidis Anastasia Oikonomou Demosthenes Bouros |
| author_facet | Argyris Tzouvelekis Nikolaos Galanopoulos Evangelos Bouros George Kolios George Zacharis Paschalis Ntolios Andreas Koulelidis Anastasia Oikonomou Demosthenes Bouros |
| author_sort | Argyris Tzouvelekis |
| collection | DOAJ |
| description | Background. Interstitial lung disease (ILD) is the most common complication of systemic sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta-analysis was to provide an estimate of the safety and efficacy profile of Mycophenolate Mofetil (MMF) or sodium (MMS) in SSc-ILD patients. Materials and Methods. All studies were reviewed systematically. The main end-points were safety and efficacy profile as estimated by forced vital capacity (FVC)% and diffusion capacity of the lung for carbon monoxide (DLCO)% of the predicted normal value (%pred.) before and after treatment in patients with SSc-ILD. Quality assessment and data extraction were performed independently by two reviewers. Results. Seventeen studies were reviewed systematically. Six studies, one prospective, were eligible for analysis encompassing 69 patients, including 10 subjects from our, yet unpublished, retrospective study. There was no statistically significant difference in both efficacy outcomes of interest, including FVC% pred. (weighted mean difference 1.48, 95% confidence interval (CI): −2.77 to 5.72, P=0.49) and DLCO % pred. (weighted mean difference −0.83, 95% CI: −4.75 to 3.09, P=0.93). No cases of clinically significant side effects were documented. Conclusions. Meta-analysis data suggest that MMF is a safe therapeutic modality which was associated with functional stabilization in patients with SSc-ILD. |
| format | Article |
| id | doaj-art-a079464296514359b56c9ace0d310ac2 |
| institution | Kabale University |
| issn | 2090-1836 2090-1844 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Medicine |
| spelling | doaj-art-a079464296514359b56c9ace0d310ac22025-02-03T05:59:05ZengWileyPulmonary Medicine2090-18362090-18442012-01-01201210.1155/2012/143637143637Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-AnalysisArgyris Tzouvelekis0Nikolaos Galanopoulos1Evangelos Bouros2George Kolios3George Zacharis4Paschalis Ntolios5Andreas Koulelidis6Anastasia Oikonomou7Demosthenes Bouros8Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Rheumatology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceLaboratory of Pharmacology, Democritus University of Thrace, 68100 Alexandroupolis, GreeceLaboratory of Pharmacology, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Radiology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceBackground. Interstitial lung disease (ILD) is the most common complication of systemic sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta-analysis was to provide an estimate of the safety and efficacy profile of Mycophenolate Mofetil (MMF) or sodium (MMS) in SSc-ILD patients. Materials and Methods. All studies were reviewed systematically. The main end-points were safety and efficacy profile as estimated by forced vital capacity (FVC)% and diffusion capacity of the lung for carbon monoxide (DLCO)% of the predicted normal value (%pred.) before and after treatment in patients with SSc-ILD. Quality assessment and data extraction were performed independently by two reviewers. Results. Seventeen studies were reviewed systematically. Six studies, one prospective, were eligible for analysis encompassing 69 patients, including 10 subjects from our, yet unpublished, retrospective study. There was no statistically significant difference in both efficacy outcomes of interest, including FVC% pred. (weighted mean difference 1.48, 95% confidence interval (CI): −2.77 to 5.72, P=0.49) and DLCO % pred. (weighted mean difference −0.83, 95% CI: −4.75 to 3.09, P=0.93). No cases of clinically significant side effects were documented. Conclusions. Meta-analysis data suggest that MMF is a safe therapeutic modality which was associated with functional stabilization in patients with SSc-ILD.http://dx.doi.org/10.1155/2012/143637 |
| spellingShingle | Argyris Tzouvelekis Nikolaos Galanopoulos Evangelos Bouros George Kolios George Zacharis Paschalis Ntolios Andreas Koulelidis Anastasia Oikonomou Demosthenes Bouros Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis Pulmonary Medicine |
| title | Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis |
| title_full | Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis |
| title_fullStr | Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis |
| title_full_unstemmed | Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis |
| title_short | Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis |
| title_sort | effect and safety of mycophenolate mofetil or sodium in systemic sclerosis associated interstitial lung disease a meta analysis |
| url | http://dx.doi.org/10.1155/2012/143637 |
| work_keys_str_mv | AT argyristzouvelekis effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT nikolaosgalanopoulos effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT evangelosbouros effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT georgekolios effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT georgezacharis effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT paschalisntolios effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT andreaskoulelidis effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT anastasiaoikonomou effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis AT demosthenesbouros effectandsafetyofmycophenolatemofetilorsodiuminsystemicsclerosisassociatedinterstitiallungdiseaseametaanalysis |